期刊文献+

一种新的鸟氨酸氨基甲酰转移酶基因突变E122G的鉴定 被引量:6

Molecular characterization of a new mutation E122G of human ornithine transcarbamylase gene
原文传递
导出
摘要 目的 测定 1个迟发型鸟氨酸氨基甲酰转移酶 (ornithine transcarbamylase,OTC)缺乏症的中国汉族家系的基因突变及患者 OTC基因外显子序列。方法 用聚合酶链反应 -单链构象多态性结合PCR产物直接测序 ,鉴定其突变类型。结果 在该家系患者 OTC基因中确认了 1个新的错义突变E12 2 G,位于第 4外显子的保守残基 (GAA→ GGA)。结论  OTC基因中 E12 2 G突变引起迟发型 OTC缺乏症 ,是 Objective: To determine the molecular basis of late onset ornithine transcarbamylase (OTC) deficiency in a Chinese family of Han nationality and the exon sequences of OTC gene of this patient. Methods: Polymerase chain reaction-single strand conformation polymorphism and direct sequencing were used to identify the mutation type. Results: A missense mutation E122G in the conserved residue of exon 4 was identified, which is unreported before. Conclusion: The E122G mutation in human OTC gene may cause late onset OTC deficiency.
出处 《中华医学遗传学杂志》 EI CAS CSCD 2003年第1期19-22,共4页 Chinese Journal of Medical Genetics
  • 相关文献

参考文献2

  • 1R. Hoshide,T. Matsuura,S. Komaki,E. Koike,I. Ueno,I. Matsuda. Specificity of PCR-SSCP for detection of the mutant ornithine transcarbamylase (OTC) gene in patients with OTC deficiency[J] 1993,Journal of Inherited Metabolic Disease(5):857~862
  • 2Toshinobu Matsuura,Ryuuji Hoshide,Chiaki Setoyama,Kazunori Shimada,Yutaka Hase,Toshihiko Yanagawa,Mitsuharu Kajita,Ichiro Matsuda. For novel gene mutations in five Japanese male patients with neonatal or late onset OTC deficiency: application of PCR-single-strand conformation polymorphisms for all exons and adjacent introns[J] 1993,Human Genetics(1):49~56

同被引文献84

  • 1郭翔,胡普信,徐岩,赵光鳌.黄酒挥发性风味物质的研究[J].酿酒科技,2004(5):79-81. 被引量:43
  • 2陈宜宜,张文悦,瞿素莲.黄酒中尿素的测定[J].环境污染与防治,1996,18(3):34-36. 被引量:17
  • 3Lindgren V,de Martinville B,Horwich AL,et al. Humanornithine transcarbamylase locus mapped to band Xp21. I nearthe Duchenne muscular dystrophy locus[J]. Science,1984,226:698-700.
  • 4Horwich AL, Kalousek F, Fenton WA, et al. Targeting of pre-ornithine transcarbamylase to mitochondria: definition of criticalregions and residues in the leader peptideQ]. Cell,1986,44:451-459.
  • 5Brusilow SWf Maestri NE. Urea cycle disorders: diagnosis,pathophysiology, and therapy [J]. Adv Pediatr,1996,43:127-170.
  • 6Wilcken B. Problems in the management of urea cycle disorders[J]. Mol Genet Metab,2004,81(Suppl 1);S86-91.
  • 7Hudak ML, Jones MD Jr, Brusilow SW. Differentiation oftransient hyperammonemia of the newborn and urea cycle enzymedefects by clinical presentation [J]. J Pediatr,1985 ,107: 712-719.
  • 8Fernandes J, Saudubray JM, van den Berghe G,et al. Inbornmetabolic diseases: diagnosis and treatment [ M ].4th ed.Germany:Springer Medizin Verlag Heidelberg,2006.267.
  • 9Steiner RD,Cederbaum SD. Laboratory evaluation of urea cycledisorders[J]. J Pediatr,2001,138:S21-29.
  • 10Kim GH, Choi JH, Lee HH, et al. Identification of novelmutations in the human ornithine transcarbamylase (OTC) geneof Korean patients with OTC deficiency and transient expressionof the mutant proteins in vitro[J]. Hum Mutat,2006 ,27:1159.

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部